Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Cited by (197)

Items 101–197 of 197

1. Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide
   on behalf of the German Adrenocortical Carcinoma Study Group, Matthias Kroiß, Timo Deutschbein, Wiebke Schlötelburg, Cristina Lucia Ronchi, Bruno Neu, Hans‐Helge Müller, Marcus O. Quinkler, Stefanie Hahner, Anke Heidemeier et al. · 2016 · Hormones and Cancer
2. Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China
   Yongshuo Ji, Yu Zhang, Junqiu Zhu, Linglin Zhu, Yanfei Zhu, Kaimeng Hu, Hong Zhao · 2018 · Cancer Management and Research
3. Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment
   Balaji Krishnamachary, Yelena Mironchik, Desmond Jacob, Eibhlin S. Goggins, Samata M. Kakkad, Francis Ofori, Louis Doré-Savard, Santosh Kumar Bharti, Flonné B. Wildes, Marie‐France Penet et al. · 2020 · Neoplasia
4. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies
   Pedro Luiz Serrano Usón, Fernanda Davila Sampaio Tolentino, Vanessa Montes Santos, Edna Terezinha Rother, Fernando Cotait Maluf · 2020 · PLoS ONE
5. Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment
   Jennifer M. Finan, Yifei Guo, Shaun M. Goodyear, Jonathan Robert Brody · 2024 · JCO oncology advances.
6. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide
   Francis W. Hunter, Jules B. L. Devaux, Fanying Meng, Cho Rong Hong, Aziza Khan, Peter Tsai, Troy W. Ketela, Indumati Sharma, Purvi M. Kakadia, Stefano Marastoni et al. · 2019 · Molecular Pharmacology
7. Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor Hypoxia
   Kameliya Anichina, Nikolay Lumov, Ventsislav V. Bakov, Denitsa Y. Yancheva, Nikolai I. Georgiev · 2024 · Molecules
8. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development
   Min‐Xia Su, Lele Zhang, Zhangjian Huang, Jia-Jie Shi, Jin‐Jian Lu · 2018 · Current Drug Targets
9. Active Anchoring Stimuli‐Responsive Nano‐Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment
   Mingxing Li, Xuwei Shang, Hai-ya Lou, Zixu Wang, Shanshan Xiang, Yihe Qiu, Fuqiang Hu, Fangying Yu, Hong Yuan · 2024 · Advanced Healthcare Materials
10. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
    Angela Diana, Lai Mun Wang, Zenobia D’Costa, Abul Azad, Michael A. Silva, Zahir F. Soonawalla, Paul Allen, Stanley K. Liu, William Gillies McKenna, Ruth J. Muschel et al. · 2016 · Oncotarget
11. Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments
    Kyung Seo Joo, Sun Jin Sym, Kwangmin Kim, Dongwoo Khang · 2025 · International Journal of Nanomedicine
12. Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
    Angel A. Dominguez, M Perz, Yi Xu, Leonor G. Cedillo, O L Huang, Caitlin A. McIntyre, Vignesh Vudatha, Jose Gilberto Trevino, Jun Liu, Pei Wang · 2024 · Cancers
13. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy
    Yvain Gérard, Aurélien Voissière, Caroline Peyrode, Marie‐Josèphe Galmier, Elise Maubert, Donia Ghedira, Sébastien Tarrit, Vincent Gaumet, Damien Canitrot, Élisabeth Miot-Noirault et al. · 2020 · Bioorganic Chemistry
14. Recent Advances in the Development of Pro-PROTAC for Selective Protein Degradation
    Fady T. Hakem, Ahmad Abdelwaly, Reem Alshaman, Abdullah Alattar, Fawaz E. Alanazi, Sawsan A. Zaitone, Mohamed A. Helal · 2025 · Pharmaceutics
15. Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
    Sofia Parrasia, Mario Zoratti, Ildikò Szabó, Lucia Biasutto · 2020 · Cellular Physiology and Biochemistry
16. Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer
    Mikaela Dell’Oro, Michala Short, Puthenparampil Wilson, Eva Bezak · 2020 · Cancers
17. Exploiting tumor hypoxia for cancer treatment
    Niemans · 2018
18. Realistic biological approaches for improving thermoradiotherapy
    Michael R. Horsman · 2015 · International Journal of Hyperthermia
19. Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
    Vasilios Liapis, Aneta Zysk, Mark O. DeNichilo, Irene Zinonos, Shelley J. Hay, Vasilios Panagopoulos, Alexandra Jayne Shoubridge, Christopher Difelice, Vladimir Ponomarev, Wendy V. Ingman et al. · 2017 · Cancer Medicine
20. Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials
    Zhiyi Zhang, Jie Song, Cao Xie, Jun Pan, Weiyue Lu, Min Liu · 2021 · The AAPS Journal
21. Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma
    Archana Bhaw‐Luximon, Nowsheen Goonoo, Dhanjay Jhurry · 2016 · Elsevier eBooks
22. FMISO as a Biomarker for Clinical Radiation Oncology
    Sebastian Zschaeck, Jörg Steinbach, Esther G.C. Troost · 2016 · Recent results in cancer research/Recent Results in Cancer Research
23. Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer
    Robert F. Anderson, Dan Li, Francis W. Hunter · 2017 · Free Radical Biology and Medicine
24. Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000
    Xinjian Mao, Sarah P. McManaway, Jagdish Kumar Jaiswal, Cho Rong Hong, William Robert Wilson, Kevin Owen Hicks · 2019 · Cancer Biology & Therapy
25. Hypoxic microenvironment in cancer: role in metabolic reprogramming
    Sureka, Niti, Maheshwari, Rashi, Agravat, Amit, Singhal, Shweta, Zaman, Shamsuz, Rishi, Bhavika, Siraj, Fouzia, Zaheer, Sufian, Misra, Aroonima · 2026 · Frontiers in Oncology
26. Nouveautés dans la biologie du cancer du pancréas
    Louis Buscail, Barbara Bournet, Marlène Dufresne, Jérôme Torrisani, Pierre Cordelier · 2015 · Bulletin du Cancer
27. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain
    Celine Yeh, Susan Elaine Bates · 2021 · Seminars in Oncology
28. Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
    Quentin Bailleul, Pauline Navarin, Mélanie Arcicasa, Christine Mahieu, Angel Montero Carcaboso, Xuefen Le Bourhis, Alessandro Furlan, Samuel Meignan, Pierre Leblond · 2021 · Cancers
29. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia
    Sandeep Pandey, Ranjana Singh, Nimra Habib, Ramesh Tripathi, Rashmi Kushwaha, Abbas Ali Mahdi · 2024 · Asian Pacific Journal of Cancer Prevention
30. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
    Caroline Fong, Emma Burke, David Cunningham, Naureen Starling · 2019 · Gastroenterology Research and Practice
31. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs
    Ying Huang, Chen Jin, Jiahui Yu, Lei Wang, Wei Ping Lu · 2020 · Bioorganic Chemistry
32. Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
    Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
33. Phase I study of pazopanib plus TH-302 in advanced solid tumors
    Richard F. Riedel, Kellen L. Meadows, Paula H. Lee, Michael Andrew Morse, Hope Elizabeth Uronis, Gerard C. Blobe, Daniel J. George, Jeffrey Crawford, Donna Niedzwiecki, Christel N. Rushing et al. · 2017 · Cancer Chemotherapy and Pharmacology
34. Emerging antibodies for the treatment of pancreatic cancer
    Kalliopi Andrikou, Chiara Peterle, Stefania Pipitone, Massimiliano Salati, Stefano Cascinu · 2017 · Expert Opinion on Emerging Drugs
35. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)
    Nguyen H. Tran, Nathan R. Foster, Amit Mahipal, Thomas Byrne, Joleen Marie Hubbard, Alvin Silva, Kabir Mody, Steven R. Alberts, Mitesh J. Borad · 2021 · Investigational New Drugs
36. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
    Maria Rosaria Abbattista, Amir Ashoorzadeh, Christopher P. Guise, Alexandra M. Mowday, Rituparna Mittra, Shevan Silva, Kevin Owen Hicks, Matthew R. Bull, Victoria Jackson-Patel, Xiaojing Lin et al. · 2021 · Pharmaceuticals
37. Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.
    E. Jouberton, Aurélien Voissière, Frederique Madeleine Penault-Llorca, F. Cachin, Élisabeth Miot-Noirault · 2022 · PubMed Central
38. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses
    Julius Strauss, Christine Alewine, William Douglas Figg, Austin G. Duffy · 2015 · Clinical & Translational Oncology
39. Discovery of the Hypoxia-Activated Prodrug SN30000
    Michael P. Hay, Kevin Owen Hicks, William Robert Wilson · 2016 · Elsevier eBooks
40. Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers
    Cho Rong Hong, Jingli Wang, Kevin Owen Hicks, Michael P. Hay · 2016 · Advances in experimental medicine and biology
41. Working with Hypoxia
    Elizabeth Bowler, Michael Ladomery · 2019 · Methods in molecular biology
42. Extrinsic and Cell-Intrinsic Stress in the Immune Tumor Micro-Environment
    Aldo Ummarino, Nicholas Calà, Paola Allavena · 2024 · International Journal of Molecular Sciences
43. Evofosfamide Enhances Sensitivity of Breast Cancer Cells to Apoptosis and Natural-Killer-Cell-Mediated Cytotoxicity Under Hypoxic Conditions
    Shubhankar Das, Goutham Hassan Venkatesh, Walid El‐Sayed, Raefa Abou Khouzam, Ayda Shah Mahmood, Husam Hussein Nawafleh, Nagwa Ahmed Zeinelabdin, Rania Faouzi Zaarour, Salem Chouaı̈b · 2025 · Cancers
44. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma
    Hani M. Babiker, Irbaz Bin Riaz, S. Shah, Daniel D. Von Hoff, Mitesh J. Borad · 2016 · Anti-Cancer Drugs
45. Hypoxia
    Corbin C. Jensen, Noel A. Warfel · 2021 · Elsevier eBooks
46. New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results
    Rubén López-Benítez, David Benz, Yue Wu, Xin-ping Wu, Samuel L. Chen, Gregory M. Cruise · 2017 · CardioVascular and Interventional Radiology
47. Virus-directed enzyme prodrug therapy and the assessment of the cytotoxic impact of some benzimidazole derivatives
    Michał Szewczuk, Karolina Boguszewska, Marta Żebrowska-Nawrocka, Ewa Izabela Balcerczak, Marta Stasiak, Maria Świątkowska, Katarzyna Błaszczak-Świątkiewicz · 2017 · Tumor Biology
48. The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective
    Michele Reni, Umberto Peretti, Silvia Matilde Zanon · 2017 · Endoscopic Ultrasound
49. MRI assessment of changes in tumor oxygenation post hypoxia-targeted therapy
    Shubhangi Agarwal, Rohini Vidya Shankar, Landon J. Inge, Vikram D. Kodibagkar · 2015 · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
50. Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance
    Maliheh Hasannia, Mahdi Abounoori, Fatemeh Mahmoudian, Maryam Shirzad, Abbas Rahdar, Selamu Duguna, Sadanand Pandey · 2026 · Frontiers in Oncology
51. High Intensity Focused Ultrasound Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma: A Propensity Score‐Matching Analysis
    Jiwei Ning, Shifeng Wang, Yuehao Guo, Jianfeng Diao, Xuehong Bai, Hongjin Wang, Kaimeng Hu, Qingwen Zhao · 2023 · Journal of Ultrasound in Medicine
52. TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing's sarcoma cells under hypoxia
    Marie Kühne, Sabine Becker, Jürgen Sonnemann, Christian Marx · 2025 · Clinical & Translational Oncology
53. Prodrug-based drug delivery approaches in cancer combination therapy
    FERAY TURA KOCKAR, Esra TOKAY, Nelin Hacıoğlu · 2022 · Elsevier eBooks
54. Cancer metabolism in gastrointestinal cancer
    Hideo Baba, Hiroshi Sawayama, Nobutomo Miyanari · 2015 · Journal of Cancer Metastasis and Treatment
55. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis
    Shuisheng Zhang, Weimin Xie, Yinghua Zou, Shuanghua Xie, Jianwei Zhang, Wei Yuan, Jie Ma, Jiuda Zhao, Cuiling Zheng, Yingtai Chen et al. · 2018 · Cancer Management and Research
56. Hypoxia‐targeting therapy for intestinal T‐cell lymphoma in dogs: Preclinical study using 3D in vitro models
    Hiroki Yamazaki, Toshiyuki T. Tanaka, Hidetaka Nishida, Shingo Hatoya, Hideo Akiyoshi · 2022 · Veterinary and Comparative Oncology
57. Anticancer effect of arsenite on cell migration, cell cycle and apoptosis in human pancreatic cancer cells
    Yohei Horibe, SEIJI ADACHI, Ichiro Yasuda, TAKAHIRO YAMAUCHI, Junji Kawaguchi, Osamu Kozawa, Masahito Shimizu, Hisataka Moriwaki · 2016 · Oncology Letters
58. Coenzyme Q10 as an Inhibitor of Effector Release from One-Electron-Reduced Bioreductive Anticancer Prodrugs
    Robert F. Anderson, Wen Qi · 2025 · Molecules
59. Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer
    Mónica Tang, Julia Chen, David Goldstein, Matthew Jon Links, Sarah J. Lord, Ian C. Marschner, Robert John Simes, Chee Khoon Lee · 2019 · Pancreas
60. Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
    Manuel Olazábal-Morán, C. Blázquez-Barbadillo, E. Pérez-Izquierdo, M. Muñoz-Silva, A. Garrido · 2026 · Advanced Drug Delivery Reviews
61. Systemic therapy for metastatic pancreatic cancer
    Robert Anthony Zaiden, Louise Zhou, George P. Kim · 2015 · Translational Cancer Research
62. Emerging Systemic and Targeted Therapies
    Trailokya Nath Pandit, Philip A. Philip · 2015 · Springer eBooks
63. Pancreatic Cancer and Possible Therapeutic Options
    Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal, Sarfraz Ahmad · 2019 · Elsevier eBooks
64. Real-world response of patients with locally advanced pancreatic adenocarcinoma to high intensity focused ultrasound treatment: a single-center, observational study in China
    Congye Wu, Xinmei Wu, Huanyu Zhao, Dongying Gu, Xiaowei Wei, Cuiju Tang, Jinfei Chen · 2018 · Translational Cancer Research
65. The importance of niche in therapeutic strategies targeting normal and cancer stem cells
    Sparsh Agarwal, Linkon Saha, Advait Sohani, Urekha Karri, Ravi Gor, Satish Ramalingam · 2023 · Elsevier eBooks
66. Standards de chimiothérapie, perspectives et thérapies ciblées dans l’adénocarcinome du pancréas
    Aurélien Lambert, Thierry Conroy · 2015 · ONCOLOGIE
67. Hypoxia-Induced Stress Responses in Cancer and Cancer Stem Cells
    Sandhya Chipurupalli, Snehlata Kumari, Vincenzo Desiderio, Nirmal Robinson · 2022 · Springer eBooks
68. Overcoming tumor hypoxia
    Alexander Marie-Madeleine Adrianus van der Wiel · 2023
69. TH-302 – ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom
    Claudia Schmalz, Jürgen Dunst · 2015 · Strahlentherapie und Onkologie
70. The hypoxic tumor microenvironment: from imaging to targeting
    Sarah G.J.A. Peeters · 2015
71. Development of Hypoxia: Activated Cytotoxic Prodrug
    Takuya Tsunoda · 2017 · Springer eBooks
72. Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed
    Namrata Vijayvergia, Steven J. Cohen · 2017 · Springer eBooks
73. Hypoxia-selective antitumor prodrugs and fluorescent probes
    Xiulong Shen · 2016
74. Developing Targeted Therapy against Pancreatic Cancer
    Garima Kaushik · 2019 · DigitalCommons@UNMC
75. Novel Targeted Treatment Approaches in Pancreatic Cancer
    Maria Diab, Muhammad Saad Hamid, Ramzi M. Mohammad, Philip A. Philip, Asfar Sohail Azmi · 2019 · Springer eBooks
76. Treatment of Advanced Pancreatic Carcinoma
    Anteneh A. Tesfaye, Philip A. Philip · 2019 · Springer eBooks
77. What Are the New Challenges of the Current Cancer Biomarkers?
    Jie Chen, Liqiong Yang, Yuxi Duan, Tinging Pu, Sha Zheng, Fangfang Liu, Kun Huang, Greg Mirt, Fan Xu · 2019 · IntechOpen eBooks
78. Protonentherapie von Rhabdomyosarkompatienten im Kindesalter Gleiche lokale Tumorkontrolle wie bei Photonentherapie mit weniger Nebenwirkungen
    Kristin Gurtner, Michael A. Baumann · 2015 · Strahlentherapie und Onkologie
79. Hypoxia Induced Stress Responses in Cancer and Cancer-Stem Cells
    Sandhya Chipurupalli, Snehlata Kumari, Vincenzo Desiderio, Nirmal Robinson · 2021 · Springer eBooks
80. Imaging of tumor hypoxia with PET
    Catharina M.L. Zegers · 2016
81. Optimizing the treatment of oesophageal cancer
    Van De Voorde Lien · 2020
82. Targeting epigenetic modifiers in breast cancer
    Francesco Casciello · 2020 · Queensland University of Technology
83. Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach
    Nikhil Ponnoor Anto, Rashmi Mittal · 2023 · BENTHAM SCIENCE PUBLISHERS eBooks
84. The Synthesis and Biological Evaluation of Ligands for C-Type Lectin Receptors
    Ayesha Khan · 2023
85. AGENTES ANTINEOPLÁSICOS BIORREDUTÍVEIS: AVANÇOS E DESAFIOS APÓS 20 ANOS
    Pedro Augusto Lemos Santana, Gabriel Marques, Mariana Cortezzi, Ricardo José Alves, Renata Barbosa de Oliveira · 2023 · Química Nova
86. Hypoxia and Tumor Immunity
    Manish Kumar, Sonia Thapa, Anurag Sankhyan · 2025 · Springer eBooks
87. Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic cancer—insights from an in silico study
    Melissa Anne McIntyre, Puthenparampil Wilson, Peter Gorayski, Eva Bezak · 2025 · Physics in Medicine and Biology
88. Modélisation des interactions entre trois médicaments actifs sur une lignée cellulaire de cancer du pancréas
    Emilie A.G. Molins · 2020
89. Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
    Audrey Lequeux · 2020 · theses.fr (ABES)
90. Bioreductive Activated Prodrugs to Target Tumor Hypoxia
    Emilie Anduran · 2022
91. HIFs: The central drivers of tumors and their role as molecular switches in targeted therapy?
    Yi Peng, Ying Che, Yingqi Zhao, Zheng Wang, Zhanlei Pei, Yanyun Hu, Yuhang Yin, Xiaolong Pan, Xiaoyun Hu, Minjie Wei et al. · 2026 · Acta Pharmaceutica Sinica B
92. Hypoxia-responsive nanocarriers for biomedical application
    Mohammad Hossein Karami, Omid Moini Jazani · 2026 · Elsevier eBooks
93. Tumour hypoxia in clinical oncology: imaging, therapeutic strategies, and translational challenges
    Xuehua Lin, Maitiú Ó Murchú, Luke Sheridan, Soumya Menon, Gerard G. Hanna, Helena M. Kelly, Christopher R. Simpson · 2026 · Clinical and Translational Radiation Oncology
94. Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation
    Jinru Yang, Xing Cai, Fajian He, 张君红, Ziqiang Zhang, Zongbi Yi, Conghua Xie, Binghe Xu · 2026 · Signal Transduction and Targeted Therapy
95. Niches in cancer: from primary tumors to metastatic disease
    Zheng Chao, Xiaojing Wang, Zhihua Wang, Kongming Wu, Le Li · 2026 · Journal of Hematology & Oncology
96. Tumor microenvironment-driven therapeutic resistance in pancreatic ductal adenocarcinoma
    Hongjia Li, Jianing Cui, Xin Yang, Jia-Hang Li, Qin-Cheng Zhao, Chun-Jie Li, Qiang Fu, Jun-Ying Li, Yu Zhou, Shi-Kai Zhu · 2026 · Cancer Drug Resistance
97. BindingDB Entry 50020203: Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
    BindingDB · 2024 · UC San Diego